Bavunalimab

帕那利单抗

Report date: 2025/04/28 15:38:44

Base Information

Drug NameBavunalimab
Drug Alias NamePavunalimabXmAb-22841XmAb-841
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitorsCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsLymphocyte activation gene 3 proteinCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursProstatic Neoplasms +[22] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursProstatic Neoplasms +[22] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A